JPWO2023022229A5 - - Google Patents
Info
- Publication number
- JPWO2023022229A5 JPWO2023022229A5 JP2023542460A JP2023542460A JPWO2023022229A5 JP WO2023022229 A5 JPWO2023022229 A5 JP WO2023022229A5 JP 2023542460 A JP2023542460 A JP 2023542460A JP 2023542460 A JP2023542460 A JP 2023542460A JP WO2023022229 A5 JPWO2023022229 A5 JP WO2023022229A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- nucleic acid
- acid strand
- bases
- nucleosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021134443 | 2021-08-19 | ||
| PCT/JP2022/031385 WO2023022229A1 (ja) | 2021-08-19 | 2022-08-19 | モルホリノ核酸を含む修飾ヘテロ核酸 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023022229A1 JPWO2023022229A1 (https=) | 2023-02-23 |
| JPWO2023022229A5 true JPWO2023022229A5 (https=) | 2025-08-26 |
Family
ID=85239875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542460A Pending JPWO2023022229A1 (https=) | 2021-08-19 | 2022-08-19 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250339459A1 (https=) |
| EP (1) | EP4389891A4 (https=) |
| JP (1) | JPWO2023022229A1 (https=) |
| WO (1) | WO2023022229A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2026034445A1 (ja) * | 2024-08-05 | 2026-02-12 | 日本新薬株式会社 | ホスホロジアミデートモルフォリノオリゴ核酸（ｐｍｏ）とポリアニオンとを含む、ｐｍｏ複合体 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5955599A (en) | 1995-06-01 | 1999-09-21 | Hybridon, Inc. | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| CA2666191C (en) | 2006-10-09 | 2017-07-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pcsk9 |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| JP6112569B2 (ja) * | 2011-12-16 | 2017-04-12 | 国立大学法人 東京医科歯科大学 | キメラ２重鎖核酸 |
| EP3004347B1 (en) * | 2013-05-30 | 2018-09-26 | National University Corporation Tokyo Medical and Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| AU2014282666A1 (en) * | 2013-06-16 | 2016-01-07 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| WO2015168172A1 (en) | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| WO2016081600A1 (en) | 2014-11-18 | 2016-05-26 | Zata Pharmaceuticals, Inc. | Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds |
| US20160319278A1 (en) * | 2015-04-03 | 2016-11-03 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| US11260134B2 (en) * | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| EP3769769A4 (en) * | 2018-03-19 | 2022-05-04 | National University Corporation Tokyo Medical and Dental University | NUCLEIC ACID WITH REDUCED TOXICITY |
| CN113677374A (zh) * | 2019-04-08 | 2021-11-19 | 国立大学法人东京医科齿科大学 | 肌疾病治疗用药物组合物 |
| EP4043565A4 (en) * | 2019-10-11 | 2024-01-24 | National University Corporation Tokyo Medical and Dental University | MODIFIED HETERONUCLEIC ACID |
| JP7704513B2 (ja) | 2020-02-26 | 2025-07-08 | 日本製紙クレシア株式会社 | 防護服 |
-
2022
- 2022-08-19 JP JP2023542460A patent/JPWO2023022229A1/ja active Pending
- 2022-08-19 EP EP22857087.5A patent/EP4389891A4/en active Pending
- 2022-08-19 US US18/683,972 patent/US20250339459A1/en active Pending
- 2022-08-19 WO PCT/JP2022/031385 patent/WO2023022229A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2023022229A5 (https=) | ||
| US11697811B2 (en) | Oligomers | |
| CN102803284B (zh) | 用于miRNA抑制剂和模拟物的化学修饰基序 | |
| CN110832077B (zh) | 用于抑制α-ENaC表达的RNAi剂及使用方法 | |
| WO2023022229A1 (ja) | モルホリノ核酸を含む修飾ヘテロ核酸 | |
| JP7830340B2 (ja) | ＰＮＰＬＡ３の発現を阻害するためのＲＮＡｉ薬、その医薬組成物、及び使用方法 | |
| US10183977B2 (en) | Stabilized STAT3 decoy oligonucleotides and uses therefor | |
| JPWO2019177061A1 (ja) | 核酸複合体 | |
| JP7737667B2 (ja) | 核酸複合体 | |
| JP2019527549A (ja) | 転写プロセシングの調節のための化合物及び方法 | |
| IL317141A (en) | Oleic acid-conjugated oligonucleotides and uses thereof | |
| KR20240168424A (ko) | 앤지오텐시노겐 조절 조성물 및 이의 사용 방법 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP2025081562A (ja) | アンチセンス核酸の毒性を軽減する方法 | |
| US10731154B2 (en) | Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| JPWO2023042876A5 (https=) | ||
| CA2976688C (en) | Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides | |
| WO2023042876A1 (ja) | ２'－修飾ヌクレオシドを含むヘテロ核酸 | |
| JPWO2022250050A5 (https=) | ||
| CN121127248A (zh) | 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法 | |
| HK40084771B (zh) | 用於抑制PNPLA3表达的RNAi剂、其药物组合物和使用方法 | |
| KR20250164214A (ko) | 아탁신-2(ATXN2)의 발현을 억제하기 위한 RNAi 제제, 이의 조성물, 및 사용 방법 | |
| US20230416734A1 (en) | Umlilo antisense transcription inhibitors | |
| HK40084771A (en) | Rnai agents for inhibiting expression of pnpla3, pharmaceutical compositions thereof, and methods of use |